Text Size

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan

Miki A., Miyamoto E., Ishida N., Shii D., Hori K., LESPOIR Research Group


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Department of Ophthalmology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 2-15, Japan; Department of Innovative Visual Science, Osaka University Graduate School of MedicineOsaka, Japan; Japan Medical Affairs Group, Santen Pharmaceutical Co., Ltd.Osaka, Japan

Related Publications

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF


Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.


Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022